Drug-drug interactions between vitamin K antagonists and statins: a systematic review

被引:2
作者
Engell, Anna E. [1 ]
Svendsen, Andreas L. O. [2 ]
Lind, Bent S. [1 ,3 ]
Stage, Tore Bjerregaard [4 ]
Hellfritzsch, Maja [4 ,5 ]
Pottegard, Anton [4 ]
机构
[1] Copenhagen Univ Hosp Hvidovre, Dept Clin Biochem, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark
[2] Odense Univ Hosp, Dept Clin Biochem & Pharmacol, Odense, Denmark
[3] Univ Copenhagen, Dept Publ Hlth, Res Unit Gen Practice & Sect Gen Practice, Copenhagen Primary Care Lab CopLab, Copenhagen, Denmark
[4] Univ Southern Denmark, Dept Publ Hlth, Clin Pharmacol & Pharm, Odense, Denmark
[5] Aarhus Univ Hosp, Dept Clin Pharmacol, Aarhus, Denmark
关键词
Drug interactions; Statins; Anticoagulants; Vitamin K antagonists; Warfarin; WARFARIN; ROSUVASTATIN; PITAVASTATIN; USERS;
D O I
10.1007/s00228-020-03074-w
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose Concomitant use of vitamin K antagonists (VKA) and statins is frequent in cardiovascular patients. However, clinical guidelines on this drug combination are divergent. Therefore, we performed a systematic review to evaluate the effect of statin initiation on coagulation among VKA users. Methods Following the PRISMA guidelines, we applied two broad search strategies for the drug interaction between VKA and statins in both Embase and Pubmed; 8623 unique hits were obtained. In the final sample, eight studies were included. Results The most frequently used VKA in the studies was warfarin, while simvastatin was the most commonly initiated statin. All included studies showed a minor increase in the anticoagulant effect of VKA following statin initiation during VKA treatment. The reported increases in mean international normalized ratio (INR) ranged from 0.15-0.65. Conclusion The anticoagulant effect of statin initiation in patients treated with VKA is likely to be of limited clinical relevance but should be evaluated individually.
引用
收藏
页码:1435 / 1441
页数:7
相关论文
共 29 条
  • [11] The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements
    Hickmott, H
    Wynne, H
    Kamali, F
    [J]. THROMBOSIS AND HAEMOSTASIS, 2003, 89 (05) : 949 - 950
  • [12] Systematic overview of warfarin and its drug and food interactions
    Holbrook, AM
    Pereira, JA
    Labiris, R
    McDonald, H
    Douketis, JD
    Crowther, M
    Wells, PS
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) : 1095 - 1106
  • [13] Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Pitavastatin on Steady-State Warfarin in Healthy Adult Volunteers
    Inagaki, Yoichiro
    Hunt, Thomas
    Arana, Bill
    Gosho, Masahiko
    Morgan, Roger
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09) : 1302 - 1309
  • [14] Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects
    Jindal, D
    Tandon, M
    Sharma, S
    Pillai, KK
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (09) : 621 - 625
  • [15] Guidelines on oral anticoagulation with warfarin - fourth edition
    Keeling, David
    Baglin, Trevor
    Tait, Campbell
    Watson, Henry
    Perry, David
    Baglin, Caroline
    Kitchen, Steve
    Makris, Michael
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (03) : 311 - 324
  • [16] Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin
    Kim, Myong-Jin
    Nafziger, Anne N.
    Kashuba, Angela D. M.
    Kirchheiner, Julia
    Bauer, Steffen
    Gaedigk, Andrea
    Bertino, Joseph S., Jr.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 431 - 436
  • [17] Moher D, 2010, INT J SURG, V8, P336, DOI [10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2700, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.i4086]
  • [18] Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
    Neuvonen, Pertti J.
    Niemi, Mikko
    Backman, Janne T.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (06) : 565 - 581
  • [19] Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
    ODriscoll, G
    Green, D
    Taylor, RR
    [J]. CIRCULATION, 1997, 95 (05) : 1126 - 1131
  • [20] Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding Risk
    Schelleman, Hedi
    Bilker, Warren B.
    Brensinger, Colleen M.
    Wan, Fei
    Yang, Yu-Xiao
    Hennessy, Sean
    [J]. AMERICAN JOURNAL OF MEDICINE, 2010, 123 (02) : 151 - 157